Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

Yann Nguyen; Loïc Guillevin

doi:10.1055/s-0038-1669454

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2018; 39(04): 471-481
DOI: 10.1055/s-0038-1669454

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

Yann Nguyen

¹Department of Internal Medicine, Referral Center for Rare Systemic and Autoimmune Diseases, Hôpital Cochin, Université Paris Descartes, Paris, France

,

Loïc Guillevin

¹Department of Internal Medicine, Referral Center for Rare Systemic and Autoimmune Diseases, Hôpital Cochin, Université Paris Descartes, Paris, France

› Author Affiliations

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg–Strauss syndrome, is a systemic necrotizing vasculitis of small- and medium-size vessels, characterized by asthma and blood eosinophilia. EGPA typically occurs in patients with preexisting asthma, and involves the skin, lungs, and peripheral nerves. Poor-prognosis factors (i.e., involvement(s) of the gastrointestinal tract, heart, and/or kidney) have been assessed with the Five-Factor Score (FFS). One-third of the patients have anti-myeloperoxidase antineutrophil cytoplasm antibodies, and their presence seems to differentiate between two phenotypes, with different clinical characteristics and prognoses. Overall survival has improved markedly since the use of glucocorticoids and immunosuppressants, but relapse rates remain high. All patients require glucocorticoids, and for those with severe/refractory disease and FFS-defined poor prognoses, immunosuppressants should be used (cyclophosphamide for induction and azathioprine for maintenance therapy). Recent advances in EGPA management, including several novel immunomodulatory drugs and targeted biotherapies, were or are being evaluated to improve EGPA patients' prognoses.

Keywords

eosinophilic granulomatosis with polyangiitis - eosinophilia - systemic necrotizing vasculitis

Full Text

References

References
1 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27 (02) 277-301
2 Masi AT, Hunder GG, Lie JT. , et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33 (08) 1094-1100
3 Jennette JC, Falk RJ, Bacon PA. , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65 (01) 1-11
4 Vaglio A, Martorana D, Maggiore U. , et al; Secondary and Primary Vasculitis Study Group. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56 (09) 3159-3166
5 Lyons PA, Rayner TF, Trivedi S. , et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367 (03) 214-223
6 Smith K. Genetic studies in ANCA-associated vasculitis point to a new, practical disease classification based on autoantibody specificity. The 18th International Vasculitis and ANCA Workshop, Tokyo; March 2017
7 Müschen M, Warskulat U, Perniok A. , et al. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 1999; 155 (03) 915-925
8 Jakiela B, Szczeklik W, Sokolowska B. , et al. Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg-Strauss syndrome. Rheumatology (Oxford) 2009; 48 (10) 1202-1207
9 Terrier B, Bièche I, Maisonobe T. , et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 2010; 116 (22) 4523-4531
10 Tai PC, Holt ME, Denny P, Gibbs AR, Williams BD, Spry CJ. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br Med J (Clin Res Ed) 1984; 289 (6442): 400-402
11 Jakiela B, Szczeklik W, Plutecka H. , et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford) 2012; 51 (10) 1887-1893
12 Jakiela B, Sanak M, Szczeklik W. , et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2011; 29 (1, Suppl 64): S23-S34
13 Stone JH, Merkel PA, Spiera R. , et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (03) 221-232
14 Guillevin L, Pagnoux C, Karras A. , et al; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371 (19) 1771-1780
15 Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol 2013; 33 (05) 965-976
16 Vaglio A, Strehl JD, Manger B. , et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2012; 71 (03) 390-393
17 Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87 (11) 4115-4119
18 Xiao H, Heeringa P, Hu P. , et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110 (07) 955-963
19 Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51 (01) 92-99
20 Sada K-E, Amano K, Uehara R. , et al; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour, Welfare of Japan. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol 2014; 24 (04) 640-644
21 Watts RA, Lane SE, Scott DG. , et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001; 60 (12) 1156-1157
22 Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49 (03) 388-393
23 Comarmond C, Pagnoux C, Khellaf M. , et al; French Vasculitis Study Group. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65 (01) 270-281
24 Iudici M, Pagnoux C, Quartier P. , et al; French Vasculitis Study Group. Childhood- versus adult-onset ANCA-associated vasculitides: a nested, matched case-control study from the French Vasculitis Study Group Registry. Autoimmun Rev 2018; 17 (02) 108-114
25 Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol 2013; 40 (06) 929-935
26 Zwerina J, Eger G, Englbrecht M, Manger B, Schett G. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum 2009; 39 (02) 108-115
27 Bottero P, Bonini M, Vecchio F. , et al. The common allergens in the Churg-Strauss syndrome. Allergy 2007; 62 (11) 1288-1294
28 Mouthon L, Khaled M, Cohen P, Guillevin L, Mouthon L, Subra JF. Systemic small sized vessel vasculitis after massive antigen inhalation. Ann Rheum Dis 2001; 60 (09) 903-904
29 Guillevin L, Guittard T, Blétry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987; 165 (03) 165-172
30 Franco J, Artés MJ. Pulmonary eosinophilia associated with montelukast. Thorax 1999; 54 (06) 558-560
31 Hauser T, Mahr A, Metzler C. , et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 2008; 63 (08) 677-682
32 Wechsler ME, Finn D, Gunawardena D. , et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117 (03) 708-713
33 Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008; 19 (05) 364-366
34 Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest 2009; 136 (02) 507-518
35 Harrold LR, Andrade SE, Go AS. , et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32 (06) 1076-1080
36 Erzurum SC, Underwood GA, Hamilos DL, Waldron JA. Pleural effusion in Churg-Strauss syndrome. Chest 1989; 95 (06) 1357-1359
37 Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest 2000; 117 (01) 117-124
38 Herreman G, Ferme I, Puech H, Caubarrère I. [Churg and Strauss' allergic granulomatous angiitis with phrenic paralysis. 2 cases]. Nouv Presse Med 1980; 9 (47) 3631
39 Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. ; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90 (01) 19-27
40 Guillevin L, Lhote F, Gayraud M. , et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75 (01) 17-28
41 Guillevin L, Lhote F, Gallais V. , et al. Gastrointestinal tract involvement in polyarteritis nodosa and Churg-Strauss syndrome. Ann Med Interne (Paris) 1995; 146 (04) 260-267
42 Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78 (01) 26-37
43 Dennert RM, van Paassen P, Schalla S. , et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010; 62 (02) 627-634
44 Sinico RA, Di Toma L, Maggiore U. , et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47 (05) 770-779
45 Azar N, Guillevin L, Huong Du LT, Herreman G, Meyrier A, Godeau P. Symptomatic urogenital manifestations of polyarteritis nodosa and Churg-Strauss angiitis: analysis of 8 of 165 patients. J Urol 1989; 142 (01) 136-138
46 Takanashi T, Uchida S, Arita M, Okada M, Kashii S. Orbital inflammatory pseudotumor and ischemic vasculitis in Churg-Strauss syndrome: report of two cases and review of the literature. Ophthalmology 2001; 108 (06) 1129-1133
47 Dietz A, Hübner C, Andrassy K. Makrolid-Antibiotika induzierte Vaskulitis (Churg-Strauss-Syndrom) [in English]. Laryngorhinootologie 1998; 77 (02) 111-114
48 Yokoyama A, Kohno N, Fujino S, Inoue Y, Hiwada K. IgG and IgM rheumatoid factor levels parallel interleukin-6 during the vasculitic phase in a patient with Churg-Strauss syndrome. Intern Med 1995; 34 (07) 646-648
49 Cottin V, Bel E, Bottero P. , et al; the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERM“O”P). Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J 2016; 48 (05) 1429-1441
50 Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63 (02) 65-81
51 Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14 (12) 1284-1293
52 Dunogué B, Terrier B, Cohen P. , et al; French Vasculitis Study Group. Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: a long-term retrospective study on 42 patients. Autoimmun Rev 2015; 14 (09) 774-780
53 Pugnet G, Gouya H, Puéchal X. , et al; French Vasculitis Study Group. Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients. Rheumatology (Oxford) 2017; 56 (06) 947-956
54 Carrington CB, Addington WW, Goff AM. , et al. Chronic eosinophilic pneumonia. N Engl J Med 1969; 280 (15) 787-798
55 Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore) 1998; 77 (05) 299-312
56 Allen J, Wert M. Eosinophilic pneumonias. J Allergy Clin Immunol Pract 2018; 6 (05) 1455-1461
57 Kahn J-E, Grandpeix-Guyodo C, Ackermann F, Charles P, Legrand F, Blétry O. Syndromes hyperéosinophiliques: actualités physiopathologiques et thérapeutiques. [in English]. Rev Med Interne 2010; 31 (04) 268-276
58 Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27 (03) 389-413
59 Ogbogu PU, Bochner BS, Butterfield JH. , et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124 (06) 1319-25.e3
60 Groh M, Pagnoux C, Baldini C. , et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26 (07) 545-553
61 Sinico RA, Di Toma L, Maggiore U. , et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52 (09) 2926-2935
62 Sablé-Fourtassou R, Cohen P, Mahr A. , et al; French Vasculitis Study Group. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143 (09) 632-638
63 Mukhtyar C, Guillevin L, Cid MC. , et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68 (03) 310-317
64 Ribi C, Cohen P, Pagnoux C. , et al; French Vasculitis Study Group. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58 (02) 586-594
65 Puéchal X, Pagnoux C, Baron G. , et al; French Vasculitis Study Group. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg–Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol 2017; 69 (11) 2175-2186
66 Yates M, Watts RA, Bajema IM. , et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (09) 1583-1594
67 Cohen P, Pagnoux C, Mahr A. , et al; French Vasculitis Study Group. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57 (04) 686-693
68 Guillevin L, Cordier JF, Lhote F. , et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40 (12) 2187-2198
69 de Groot K, Harper L, Jayne DRW. , et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10) 670-680
70 Harper L, Morgan MD, Walsh M. , et al; EUVAS Investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71 (06) 955-960
71 Pagnoux C, Quéméneur T, Ninet J. , et al; French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 2015; 67 (04) 1117-1127
72 Hiemstra TF, Walsh M, Mahr A. , et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304 (21) 2381-2388
73 Pagnoux C, Mahr A, Hamidou MA. , et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359 (26) 2790-2803
74 Samson M, Puéchal X, Devilliers H. , et al; French Vasculitis Study Group. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013; 43 (Suppl C): 60-69
75 Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004; 63 (12) 1649-1654
76 Tsurikisawa N, Taniguchi M, Saito H. , et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92 (01) 80-87
77 Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42 (06) 1149-1153
78 Walsh M, Casian A, Flossmann O. , et al; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84 (02) 397-402
79 Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 2010; 28 (1, Suppl 57): 24-30
80 Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26 (3, Suppl 49): S35-S40
81 Pepper RJ, Fabre MA, Pavesio C. , et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47 (07) 1104-1105
82 Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 2013; 15 (05) R133
83 Mohammad AJ, Hot A, Arndt F. , et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016; 75 (02) 396-401
84 Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68 (04) 606-606
85 Bargagli E, Rottoli P. Omalizumab treatment associated with Churg-Strauss vasculitis. Int Arch Allergy Immunol 2008; 145 (03) 268
86 Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma 2016; 53 (02) 201-206
87 Jachiet M, Samson M, Cottin V. , et al; French Vasculitis Study Group. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 2016; 68 (09) 2274-2282
88 Wechsler ME, Akuthota P, Jayne D. , et al; EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017; 376 (20) 1921-1932
89 Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155 (05) 341-343
90 Kostianovsky A, Charles P, Alves J-F. , et al; French Vasculitis Study Group. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012; 30 (1, Suppl 70): S83-S89
91 Herlyn K, Gross WL, Reinhold-Keller E. Longitudinale Effekte des strukturierten Patientenschulungsprogramms für Vaskulitispatienten [in English]. Z Rheumatol 2008; 67 (03) 206-210
92 Chumbley LC, Harrison Jr EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52 (08) 477-484
93 Gaskin G, Clutterbuck EJ, Pusey CD. Renal disease in the Churg-Strauss syndrome. Diagnosis, management and outcome. Contrib Nephrol 1991; 94: 58-65
94 Solans R, Bosch JA, Pérez-Bocanegra C. , et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40 (07) 763-771
95 Durel C-A, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Arthritis Care Res (Hoboken) 2016; 68 (03) 374-387